Ajanta Pharma 将来の成長

Future 基準チェック /36

Ajanta Pharma利益と収益がそれぞれ年間13.3%と9.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に25.4% 13.5%なると予測されています。

主要情報

13.3%

収益成長率

13.54%

EPS成長率

Pharmaceuticals 収益成長	15.6%
収益成長率	9.7%
将来の株主資本利益率	25.43%
アナリストカバレッジ	Good
最終更新日	05 May 2025

今後の成長に関する最新情報

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 02

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04

Recent updates

If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

Mar 29

What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Feb 20

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 02

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Dec 15

Branded Generics Growth And Global Expansion Will Accelerate Earnings And Market Share

Dec 14 Ajanta Pharma's strong performance in Branded Generics and effective cash management strategy indicate robust future revenue and margin improvements.

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Sep 10

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Aug 23

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

Aug 01

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Jun 01

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

Apr 05

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24

業績と収益の成長予測

NSEI:AJANTPHARM - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2028	64,573	13,699	10,177	11,065	4
3/31/2027	58,564	12,278	9,094	11,668	10
3/31/2026	52,159	10,604	6,020	8,937	10
3/31/2025	46,481	9,204	8,393	11,572	N/A
12/31/2024	45,318	8,979	N/A	N/A	N/A
9/30/2024	44,908	8,750	9,127	11,625	N/A
6/30/2024	43,326	8,538	N/A	N/A	N/A
3/31/2024	42,087	8,162	6,327	7,851	N/A
12/31/2023	40,365	7,357	N/A	N/A	N/A
9/30/2023	39,031	6,602	6,610	8,199	N/A
6/30/2023	38,128	6,215	N/A	N/A	N/A
3/31/2023	37,426	5,880	6,176	7,921	N/A
12/31/2022	37,311	6,169	N/A	N/A	N/A
9/30/2022	35,972	6,742	5,027	6,613	N/A
6/30/2022	35,439	7,136	N/A	N/A	N/A
3/31/2022	33,410	7,127	4,129	5,617	N/A
12/31/2021	32,275	7,207	N/A	N/A	N/A
9/30/2021	31,384	7,056	3,607	5,379	N/A
6/30/2021	29,695	6,799	N/A	N/A	N/A
3/31/2021	28,897	6,539	4,047	5,763	N/A
12/31/2020	28,148	6,238	N/A	N/A	N/A
9/30/2020	27,173	5,547	3,593	5,334	N/A
6/30/2020	26,441	5,008	N/A	N/A	N/A
3/31/2020	25,879	4,677	2,174	4,568	N/A
12/31/2019	24,211	4,274	N/A	N/A	N/A
9/30/2019	22,550	3,868	1,451	4,409	N/A
6/30/2019	21,563	3,958	N/A	N/A	N/A
3/31/2019	20,554	3,870	315	3,745	N/A
12/31/2018	20,654	3,926	N/A	N/A	N/A
9/30/2018	21,674	4,731	N/A	N/A	N/A
6/30/2018	21,636	4,796	N/A	N/A	N/A
3/31/2018	21,258	4,686	N/A	2,811	N/A
12/31/2017	20,590	4,882	N/A	N/A	N/A
9/30/2017	20,050	4,833	N/A	N/A	N/A
6/30/2017	19,805	4,821	N/A	N/A	N/A
3/31/2017	19,833	5,068	N/A	6,093	N/A
12/31/2016	19,386	4,908	N/A	N/A	N/A
9/30/2016	18,821	4,622	N/A	N/A	N/A
6/30/2016	18,072	4,350	N/A	N/A	N/A
3/31/2016	17,340	4,156	N/A	3,261	N/A
12/31/2015	16,809	3,692	N/A	N/A	N/A
9/30/2015	16,160	3,510	N/A	N/A	N/A
6/30/2015	15,502	3,340	N/A	N/A	N/A
3/31/2015	14,736	3,099	N/A	2,794	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AJANTPHARMの予測収益成長率 (年間13.3% ) は貯蓄率 ( 6.7% ) を上回っています。

収益対市場: AJANTPHARMの収益 ( 13.3% ) Indian市場 ( 15.5% ) よりも低い成長が予測されています。

高成長収益: AJANTPHARMの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: AJANTPHARMの収益 ( 9.7% ) Indian市場 ( 9.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: AJANTPHARMの収益 ( 9.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AJANTPHARMの自己資本利益率は、3年後には高くなると予測されています ( 25.4 %)

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/15 11:27
終値	2025/05/15 00:00
収益	2025/03/31
年間収益	2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ajanta Pharma Limited 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。25

アナリスト	機関
Rashmi Sancheti Shetty	Anand Rathi Shares and Stock Brokers Limited
null null	Anand Rathi Shares and Stock Brokers Limited
null null	Asian Markets Securities Private Limited

Ajanta Pharma 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Price target increased by 7.1% to ₹2,874

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 7.6% to ₹2,664

Price target increased by 7.4% to ₹2,440

Recent updates

Full year 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ajanta Pharma Limited to Report Q4, 2025 Results on Apr 30, 2025

If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Ajanta Pharma Limited to Report Q3, 2025 Results on Jan 30, 2025

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Branded Generics Growth And Global Expansion Will Accelerate Earnings And Market Share

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 7.1% to ₹2,874

Chief Financial Officer recently sold ₹20m worth of stock

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Executive Vice President recently sold ₹5.9m worth of stock

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 7.6% to ₹2,664

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited to Report Q1, 2025 Results on Jul 30, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2024

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Price target increased by 7.4% to ₹2,440

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q4, 2024 Final Results on May 02, 2024

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024

Ajanta Pharma Limited to Report Q3, 2024 Results on Jan 31, 2024

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Price target increased by 7.5% to ₹1,949

Second quarter 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q2, 2024 Results on Oct 31, 2023

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Price target increased by 10.0% to ₹1,652

First quarter 2024 earnings released: EPS: ₹16.53 (vs ₹13.63 in 1Q 2023)

Ajanta Pharma Limited to Report Q1, 2024 Results on Jul 27, 2023

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q3, 2023 Results on Feb 01, 2023

Insufficient new directors

Second quarter 2023 earnings: EPS misses analyst expectations

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Price target increased to ₹1,574

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Price target decreased to ₹2,335

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Insufficient new directors

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹8.1m worth of stock

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Insider recently sold ₹1.1m worth of stock

Upcoming dividend of ₹9.50 per share